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PV1 is an endothelial-specific integral membrane glycoprotein associated with the stomatal diaphragms of caveolae,
transendothelial channels, and vesiculo-vacuolar organelles and the diaphragms of endothelial fenestrae. Multiple PV1
homodimers are found within each stomatal and fenestral diaphragm. We investigated the function of PV1 within these
diaphragms and their regulation and found that treatment of endothelial cells in culture with phorbol myristate acetate
(PMA) led to upregulation of PV1. This correlated with de novo formation of stomatal diaphragms of caveolae and
transendothelial channels as well as fenestrae upon PMA treatment. The newly formed diaphragms could be labeled with
anti-PV1 antibodies. The upregulation of PV1 and formation of stomatal and fenestral diaphragms by PMA was
endothelium specific and was the highest in microvascular endothelial cells compared with their large vessel counterparts.
By using a siRNA approach, PV1 mRNA silencing prevented the de novo formation of the diaphragms of caveolae as well
as fenestrae and transendothelial channels. Overexpression of PV1 in endothelial cells as well as in cell types that do not
harbor caveolar diaphragms in situ induced de novo formation of caveolar stomatal diaphragms. Lastly, PV1 upregulation
by PMA required the activation of Erk1/2 MAP kinase pathway and was protein kinase C independent. Taken together,
these data show that PV1 is a key structural component, necessary for the biogenesis of the stomatal and fenestral
diaphragms.
INTRODUCTION
Vascular endothelium is a highly differentiated cellular
monolayer that lines the entire cardiovascular system.
Judged by its magnitude and importance for the underlying
tissues, a critical function of the endothelium is to mediate
the fluid and solute exchanges between the blood plasma
and the interstitial fluid, in short microvascular permeabil-
ity. Although the molecular mechanisms underlying this
function are still largely unknown, several endothelial spe-
cialized subcellular structures have been involved in these
processes: caveolae, transendothelial channels (TEC),
fenestrae, sinusoidal gaps, vesiculo-vacuolar organelles
(VVOs), and intercellular junctions (for reviews see Palade,
1991; Michel and Curry, 1999; Dvorak and Feng, 2001; Ben-
dayan, 2002; Stan, 2002).
One of the puzzling features of these endothelial struc-
tures is that, in select microvascular beds, caveolae, TEC and
VVOs can be provided with a stomatal diaphragm (SD;
reviewed in Stan, 2002), whereas fenestrae are subtended by
a fenestral diaphragm (FD) in all cases (i.e., in kidney peri-
tubullar capillaries, all endocrine and exocrine glands, intes-
tinal villi) except in capillaries of kidney glomerulus (re-
viewed in Roberts and Palade, 2000).
Based on electron microscopy (EM) studies, the SDs of
caveolae, TEC and VVOs and the FDs have the same mor-
phology: thin (5–7 nm) protein barrier provided with a
central density or “knob” (Palade and Bruns, 1968; Clementi
and Palade, 1969a, 1969b). The FD has an octagonal symme-
try (Maul, 1971; Bearer and Orci, 1985), being constituted of
radial fibrils starting at the rim and interweaving in a central
mesh (Bearer and Orci, 1985). The intimate structure of the
SD could not be clearly elucidated, due in part to technical
limitations caused by the slight diameter differences be-
tween the SDs (40 nm) diaphragms and their fenestral
(65 nm) counterparts. However, close examination of the
SDs of both caveolae and TEC reveals hints of the same
pattern, radial fibrils and a central mesh (Bearer and Orci,
1985).
The molecular composition of the SDs and FDs has been
investigated with “general” probes such as lectins (Simio-
nescu et al., 1982a; Pino, 1986) and cationized ferritin (Simio-
nescu et al., 1981a, 1981b, 1981b, 1982b; Bankston and Milici,
1983), which demonstrated that SDs and FDs behave differ-
ently: the former bind lectins avidly and lack anionic sites,
whereas the latter do not (Simionescu et al., 1982a) or poorly
(Pino, 1986) bind lectins and have multiple anionic sites
conferred by heparan sulfate proteoglycans (HSPGs; Simio-
nescu et al., 1981a). The HSPGs are present only on the
Article published online ahead of print. Mol. Biol. Cell 10.1091/
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‡ Corresponding author. E-mail address: Radu.V.Stan@Dartmouth.edu.
Abbreviations used: a-hPV1C, anti-human PV1C pAb; DAG,
diacyl glycerol; EC, endothelial cell; EBM2, endothelial basal
medium lacking supplements; EGM2, endothelial growth me-
dium; FD, fenestral diaphragm; hrGFP, “humanized” Renilla
green fluorescent protein; SD, stomatal diaphragm; SSM, serum-
starving medium (EBM2 with 1% BSA and 0.5% FBS); TEC,
transendothelial channels; TEM, transmission electron micros-
copy.
© 2004 by The American Society for Cell Biology 3615
luminal side of fenestrae (Simionescu et al., 1982b; Rostgaard
and Qvortrup, 1997).
Recently, we have shown that the SDs of caveolae and
TEC and the FDs of fenestrae share at least one protein,
namely PV1 (Stan et al., 1999a, 1999b). PV1 is a single-span,
60-kDa, type II membrane N-glycosylated glycoprotein with
a short intracellular tail and a long extracellular domain
(Stan et al., 1999b). There is no conserved known consensus
site in the intracellular domain across mammalian species.
The extracellular domain contains four N-glycosylation sites
near the membrane, a proline-rich region near the C–termi-
nus, and two large coiled-coil domains, suggesting a rod-
like protein (Stan et al., 2001). From the studies done so far,
PV1 seems to be endothelium specific and moreover to be
specifically associated with the SDs of caveolae and TEC and
the FDs, at both fronts of ECs (Stan et al., 1999a, 1999b). PV1
forms homodimers in situ as well as in culture (Stan, 2003).
Moreover, several PV1 homodimers have been shown to
reside in close proximity in the same diaphragm in either the
SDs in the lung or FDs in kidney (Stan, 2003).
The function of PV1 within the diaphragms is unknown as
is their precise function(s), biogenesis and regulation.
Endothelial fenestrae and TEC are inducible structures, as
shown in a considerable body of literature. The surface
density of these structures and their diaphragms can be
modulated by several pathological conditions in situ and
different factors in culture (reviewed in Roberts and Palade,
2000). Culturing ECs that have fenestrae and TECs in situ
causes a drastic reduction in the surface density of these
structures (Milici et al., 1985a; Lombardi et al., 1986). This can
be reversed by either culturing these cells on extracellular
matrix from epithelial cells (Milici et al., 1985a) or in pres-
ence of phorbol myristate acetate (PMA), retinoic acid (Lom-
bardi et al., 1986, 1987, 1988) or vascular endothelial growth
factor (VEGF; Esser et al., 1998). PMA is able to induce
fenestrae and TEC even in ECs that do not have them in situ
(e.g., ECs from umbilical vein or pulmonary artery), an effect
that is blocked by TGF. The fenestrae and TEC newly
formed in culture are morphologically similar to those from
in situ, as shown by EM (Milici et al., 1985a; Lombardi et al.,
1987). There is no data in the literature documenting the
conditions of induction of the SDs of caveolae.
Here, we have addressed the role of PV1 within the dia-
phragms and probed into their regulation and biogenesis.
We present data showing that i) PV1 has a key structural
function within both the SDs and FDs being both necessary
and sufficient for their formation and ii) PV1 upregulation
and diaphragm formation is PKC independent and is de-
pendent on the activation of Erk1/2 MAP kinase.
MATERIALS AND METHODS
Materials
ECL reagents were from Pierce-Endogen (Rockford, IL). Protein kinase C
(PKC) inhibitors (staurosporine, calphostin C, Go9068, and bis-indolilmale-
imide I) and MEK1 Inhibitors (PD98059, U0126 and its negative control
U0124) were from Calbiochem (San Diego, CA). All the other general reagents
were as reported in our previous articles.
Cells and Cell Culture
Table 1 summarizes the cell types used in this study and the culture condi-
tions.
Antibodies
Anti-human PV1C pAb (-hPV1C) was raised in chickens against a synthetic
peptide (KGPPAGIPVAPSSG single-letter code, hPV1C peptide) coupled to
BSA. The hPV1C peptide consisted of the last 12 aa from hPV1 C terminus, to
which a glycine and a lysine (in bold) were added for increased solubility and
coupling purposes, respectively. IgY purification was done as before (Stan et
al., 1999a). The anti-huPV1C pAb was affinity-purified on the huPV1C peptide
coupled to Affi-Gel10 followed by extensive cross-absorption on a BSA-
agarose column (Stan et al., 1999a). Mouse anti-FLAG mAb (clone M2),
anti-FLAG-agarose, and anti--actin mAb (clone AC15) were from Sigma (St.
Louis, MO). Mouse anti-HA.11 mAb, (clone 16B12) and anti-HA-agarose was
from Covance (Denver, PA). Rat anti-HA mAb (3F10) was from Roche (Indi-
anapolis, IN). Rabbit anticaveolin 1 pAb was purchased from BD Pharmigen-
Transduction (San Diego, CA). Rabbit anti-Erk1/2, -phospho-Erk1/2, -phos-
pho-MEK1, -phospho-Raf 1, phospho-Elk1, and -phospho- serine PKC
pseudosubstrate (PS-PKC-PS) were from Cell Signaling (Beverly, MA).
PMA Treatments
Fenestrae, TEC, and caveolar SDs were induced de novo by using a published
method (Lombardi et al., 1986) with slight modifications. Briefly, ECs were
seeded at 50% confluence in six-well plates (or as noted) and either treated
after cells have attached (i.e., 4 h postseeding) or grown to confluence on
gelatin-coated plastic dishes and then treated with 50 nM phorbol myristate
acetate (PMA) or as noted. In most experiments, the ECs were serum-starved
for 6–24 h in EBM2 supplemented with 0.5% FBS and 1% BSA (serum-
starving medium [SSM]). The PMA treatment was carried out in either SSM
or EBM2 supplemented with either 2% (HUVEC) or 5% (HDMVEC,
HLMVEC) serum. The PMA treatment of non-EC types (HDF, HEK, HeLa,
COS7) was done in their corresponding either full growth or serum-starving
media. To assess for the levels of PV1, the cells were rinsed twice in cold PBS
and solubilized in equal volumes of reducing SDS-PAGE sample buffer, and
Table 1. Cell types used
Cell type Abbreviation Species Passage Cultured on Medium Sourcea
Endothelial cells
Lung microvascular ECs HLMVEC Human 6–10 Plastic or gelatin EGM2-MV Clonetics or
VEC Tec
Dermal microvascular ECs, adult HDMVEC-Ad Human 6–10 Plastic or gelatin EGM2-MV Clonetics or
VEC Tec
Dermal microvascular ECs, neonate HDMVEC-neo Human 6–10 Plastic or gelatin EGM2-MV Clonetics
Umbilical vein ECs HUVEC Human 3–10 Plastic or gelatin EGM2 Clonetics
Nonendothelial cells
Dermal fibroblasts HDF Human 5–12 Plastic MCDB131 
EndoGro
VecTec
Embryonic kidney fibroblasts HEK293 Human Plastic DMEM, 10% FBS,
antibiotics
ATTC
Cervical epithelium cancer HeLa Human Plastic DMEM, 10% FBS,
antibiotics
ATTC
Epithelial COS7 Primate Plastic DMEM, 10% FBS,
antibiotics
ATTC
a Clonetics (San Diego, CA), VecTechnologies (Rensselaer, NY), ATCC (Manassas, VA).
R.V. Stan et al.
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the samples were boiled and used for immunoblotting with anti-hPV1C pAb
and anti–-actin to show the loading.
Immunoblotting and Densitometry
Proteins were resolved by SDS-PAGE in reducing conditions and blotted
to either nitrocellulose or PVDF membranes, which were blocked and
probed with appropriate primary antibodies followed by HRP-conjugated
reporter antibodies. The signal was detected by enhanced chemilumines-
cence by exposure to autoradiography film. Quantitation of the signal was
obtained by densitometry using an AlphaImager device (Alpha Innotech,
San Leandro, CA).
Activation of the MAPK by PMA
HUVEC and HDMVEC were used for these studies. Cells were grown to
confluence in 35-mm dishes, serum-starved in SSM for 24 h followed by
treatment with 50 nM PMA in EBM2 containing 2% (HUVEC) or 5% (HDM-
VEC) FBS for 0, 5, 10, 15, 60 min and 16–20 h. After each time point the cells
were solubilized in reducing SDS-PAGE sample buffer containing 1 mM
NaOV4, boiled, and used for immunoblotting. The phosphorylation status of
the enzymes in the MAP kinase pathway was determined with the respective
phospho-specific antibodies.
Pharmacological Inhibition of PKC and MEK-1
HUVEC and HDMVEC were used for these studies. All the inhibitor stocks
were freshly made as 1000 stocks in DMSO before the experiment. The
inhibitor solutions were kept in the dark on ice, and the treatments were
carried out in the dark (except for Calphostin C that was light activate for 15
min before addition to cells). Briefly, cells were grown to confluence, serum-
starved for 4–24 h, and treated with the inhibitors for 15–30 min before
adding PMA directly into the wells, to a final concentration of 50 nM using a
1000 stock solution freshly made in EBM2. Controls consisted of cells
treated with only the vehicle for the same lengths of time as the experimental
samples or, where applicable, a negative control for the inhibitors (e.g.,
U0124). The PV1 and -actin were checked by immunoblotting after 20–24 h.
The level of PKC activity was determined after 30 min by immunoblotting
with antiphospho-serine PKC pseudosubstrate (PS-PKC-PS) antibody. The
concentration range tested for each inhibitor was bisindolylmaleimide (10–
500 nM), Go6983 (10–500 nM), calphostin C (10–100 nM), staurosporine
(0.05–50 nM), U0126 (0.1–10 M), and PD98059 (0.25–250 M).
Constructs
Full-length human PV1 (hPV1) was PCR amplified using pfu DNA polymer-
ase (Stratagene, San Diego, CA) and forward 5TGAATTCAAATGGGTCT-
GGCCATGGAGCAC3 and reverse 5AAAAGTCGACAGCCACTGGAT-
GGGGCTACAG3 primers. The resulting DNA fragment was inserted using
the EcoRI and SalI restriction sites (in bold) in the pIRES-hrGFP-1a or pIRES-
hrGFP-2a (Stratagene) bicistronic vectors, upstream and in frame with se-
quences encoding for either a 3xFLAG or 3xHA epitopes, respectively. These
vectors also contained the hrGFP gene (humanized Renilla GFP). For colocal-
ization with endogenous caveolin 1, the constructs used contained either
PV1–3xHA or PV1–3xFlag into the pCDNA3.1() vector that lacked hrGFP
expression. Caveolin1-mRFP was as published (Wadia et al., 2004).
PV1 Gene Product Silencing Using siRNA
All the experiments were carried out in HUVECs at passage 3–8. Cells were
grown six-well plates on either gelatin or plastic to near confluence and
chemically synthesized siRNA duplexes (either 75 or 200 picomoles per well)
were transfected using Targefect-siRNA reagent (Targeting Systems, San
Diego, CA) as per manufacturer’s instructions. After 24 h, the cells were
treated with PMA for 24–72 h when they were either solubilized and pro-
cessed for immunoblotting or fixed and processed for EM (Note: the EM
studies were mostly done on cells after 72 h treatment with PMA). The
sequences used for PV1 silencing were as follows: 1) duplex1 hPV1–249:
CUUGACCAAGGAGCUCAACTT (sense) and GUUGAGCUCCUUGGU-
CAAGTT (antisense); 2) duplex 2 hPV1–258: GGAGCUCAACUUCACCAC-
CTT (sense) and GGUGGUGAAGUUGAGCUCCTT (antisense); and 3) hPV1-
scrambled control: CAGCACAUGCAUGUACACGTT (sense) and CGUGUA-
CAUGCAUGUGCUGTT (antisense).
Transfections
The transfection reagents used, such as Effectene (HUVEC; Qiagen, Valencia,
CA), Targefect F1 (HUVEC, HEK293) and Targefect F2 (COS7, HeLa; Target-
ing Systems), were used according to the manufacturer’s instructions. For
high transfection efficiency into cell types hard to transfect (HUVEC, HLM-
VEC, and HDF), the DNA was delivered by electroporation using the Nucleo-
fector device and the cell-specific kits, according to the manufacturer’s in-
structions (Amaxa, Koeln, Germany). The electroporated cells were used for
either immunofluorescence (HDF) or immunogold labeling (HDF, HUVEC,
HLMVEC) with antitag antibodies as described below.
Surface Biotinylation
All the procedure was carried out at 4°C as described in Tkachenko and
Simons (2002). Cells (2 3.5-cm dishes per condition/per experiment) were
rinsed twice (2 min, 4°C) in ice-cold PBS lacking both Ca and Mg and
incubated (15–20 min, 4°C) with 0.5 g/ml water-soluble NHSPEO4-biotin
(Pierce-Endogen) in PBS after which the biotin solution was aspirated. The
reaction was quenched by incubation (5–10 min, 4°C) with 1% BSA in PBS.
Determination of the Ratio of Surface vs. Intracellular
PV1 Pools
To determine the pool of PV1 present at the cell surface in either PMA treated
ECs or in cells transfected with tagged versions of human PV1, the surface
biotinylated cells were lysed in RIPA buffer (1% TX-100, 0.4% sodium deoxy-
cholate, and 0.1% SDS, 1 mM EDTA) with protease inhibitors cocktail (Sigma
cat. no. P2714) for 1 h at 4°C with gentle rocking, and the extract was cleared
by centrifugation (1 h, 4°C, 128,000  g, TLA45 rotor). The supernatant
containing total cellular PV1 was incubated (1 h, 4°C, end-over end) with 15
l neutravidin-agarose (Pierce-Endogen). The beads were collected by cen-
trifugation (5 min, 600  g) and washed (3  5 min, RT) in ice-cold RIPA
buffer, and the bound proteins (representing the biotinylated surface proteins)
were solubilized (2 min, 100°C) in nonreducing sample buffer for SDS-PAGE.
The supernatant was moved to another tube where it was further incubated
(O/N, 4°C) with anti-hPV1C pAb covalently coupled to Affi-Gel10 beads
(Bio-Rad, Richmond, CA). The coupling of anti-hPV1CpAb was done as
before (Stan et al., 1999a). The beads were collected by centrifugation (5 min,
600  g) and washed (3  5 min, RT) in ice-cold RIPA buffer, and the bound
PV1 (representing intracellular PV1) was solubilized (2 min, 100°C) in 100 l
nonreducing sample buffer for SDS-PAGE.
To determine the amount of PV1 bound to neutravidin and to PV1 in each
sample, equivalent volumes of the bound proteins were resolved by SDS-
PAGE, transferred to PVDF membranes, and blotted with either anti-PV1 or
anti-HA antibodies (for PMA-treated cells or cells transfected with PV1–
3xHA, respectively).
Equivalent volumes of the cell extract (starting material) and the neutravi-
din and anti-PV1 supernatants were also processed for SDS-PAGE and im-
munoblotting to show depletion of PV1 after each step.
Fluorescence-activated Cell Sorting
HUVECs were transfected with bicistronic vectors encoding for hrGFPas well
as either hPV1–3xHA or hPV1–3xFLAG. The proteins were allowed to express
for 48 h, when the cells were dissociated using an enzyme-free buffer (Cell
Dissociation Buffer; Invitrogen), centrifuged (5 min, 4°C, 300  g) and resus-
pended in cold PBS supplemented 0.5% BSA. The cells were sorted in a Becton
Dickinson FACS Vantage SE cell sorter using the CellQuest software (Becton
Dickinson, Mountain View, CA). Transfected (fluorescent) cells were collected
in warm (37°C) EGM2 medium and immediately plated at high density
(80–100%) on gelatin-coated plastic dishes. After 4–6 h, the unattached, dead
cells were washed out with serum-free medium and the viable transfected
cells were cultured for 20 more hours when they were fixed and processed for
immunogold labeling as described below.
Immunofluorescence
Either PMA-treated (with or without prior PV1-siRNA treatment) or tagged
hPV1-transfected cells were fixed (30 min, RT) in 2% paraformaldehyde in 0.1
M phosphate buffer (PB), pH 7.4, quenched by washes (3  10 min, RT) in PB
containing 0.07 M glycine, and incubation (1–2 h, RT) in 10% fetal calf serum
(FCS) in PB, followed by overnight incubation with the primary antibody
(anti-huPV1C pAb, anti-HA mAb, or anti-FLAG mAb) diluted in 1% BSA in
PBS (PBSA). Cells were washed (3  30 min, RT) in PBSA followed by
incubation (2 h, RT) with F(ab)2 fragments of either anti-chicken IgY-Texas
Red or anti-mouse IgG-Alexa 594 secondary antibodies. The cells were
washed again, mounted under coverslips using PermaFluor mounting me-
dium (ThermoShandon, Pittsburgh, PA) and examined under a microscope
equipped with appropriate filters. The images were acquired with a
Hamamatsu Orca ER CCD camera (Hamamatsu, Tustin, CA) and the Open-
Lab software (Improvison, Lexington, MA), and images were processed as
TIFF files using Adobe Photoshop 5.5. software (Adobe Systems, San Jose,
CA). For colocalization studies that entailed permeabilization, cells (HUVEC,
HDF, HEK293, COS7 and HeLa) were briefly permeabilized (10 min, RT)
using 0.1% Triton X-100 in PB after fixation, followed by blocking and labeling
with antibodies as above.
Transient expression of caveolin 1-mRFP and PV-1–3xHA_IRES_hrGFP
construct was performed using Superfect (Qiagen), and the cells were ana-
lyzed by fluorescent microscopy 48–72 h posttransfection. To label PV-1-HA,
100 l of PBS with Ca and Mg, 1% BSA and 100 ng of high affinity anti-HA
mAb (Roche) were dropped on paraffin film, and the coverslip was placed
cells-down on the top of the drop. Incubation was performed for 30 min at
4°C. Cells were washed then twice with ice-cold PBS and incubated with
Alexa-647–labeled secondary antibody (Molecular Probes, Eugene, OR) at
concentration 5 g/ml for 15 min using the procedure described above. After
washing in PBS, the coverslips were mounted on microscope slides and
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imaged within 5 min. All microscopy was done using an Olympus IX-71
microscope equipped with a Sensicam QE cooled CCD camera (Cooks, Au-
burn Hills, MI), DG-4 xenon arc light source (Sutter, Novato, CA) and 100
1.4 NA lens. QED software (Media Cybernetics, Carlsbad, CA) was used for
image acquisitions. Image processing and analysis was done using Adobe
Photoshop 7.0 and AutoDeblur 9.2 (Auto Quant Imaging, Rochester, NY).
In all fluorescence experiments the minimum number of cells examined
was 20.
Immunogold labeling was performed by a pre-embedding method as in our
past work (Stan et al., 1999a, 1999b). Cells were either PMA treated or
transfected with huPV-FLAG, followed by fixation (30 min, RT) in 2% para-
formaldehyde in 0.1 M PB, pH 7.4. Next, the cells were quenched by washes
(three times for 10 min, RT) in PBS containing 0.07 M glycine and incubation
(1–2 h, RT) in 10% fetal calf serum (FCS) in PBS followed by overnight
incubation with the primary antibody (either anti-huPV1C pAb or anti-FLAG
M2 mAb) diluted in PBSA. Cells were washed (three times for 30 min, RT) in
PBSA followed by incubation (2 h, RT) with gold-conjugated cognate second-
ary antibody, washed again (three times for 30 min, RT), and the antibody-
antigen complexes were stabilized by fixation (30 min, RT) in 2% glutaralde-
hyde in 0.1 M sodium cacodylate buffer, pH 7.3. After osmication (1 h, on ice,
in the dark) and incubation (30 min, RT, in the dark) in Kellenberger’s uranyl
acetate, the cells were dehydrated in graded ethanol. The monolayer was cut
in small (1–2 mm2) squares, which were collected as a pellet and processed for
LX-112 resin embedding. Sections (50 nm thickness) were cut in a Reichert
microtome, mounted on formvar-coated nickel or copper grids, poststained
with uranyl acetate and lead citrate, and examined and photographed in a
Philips CM 10 electron microscope (Mahwah, NJ). In some cases images
were acquired using a Gatan CCD camera and processed using either
DigitalMicrograph 3.0 (Gatan, Pleasanton, CA) or Adobe Photoshop software
(Adobe Systems). The preembedding immunocytochemistry approach allows
a larger sampling with better-preserved morphology that the classical label-
ing of ultrathin cryosections.
Morphometry
For quantitation of the surface density of SDs and FDs, the treatments were
done in triplicate. Cells were fixed and processed for resin embedding and
routine morphology with and without preembedding immunocytochemistry
with anti-PV1 or antitag (HA or Flag) antibodies, as noted. From each exper-
iment there were three blocks per condition. From each block there were five
sections examined from which 10 random pictures were acquired at a mag-
nification of 8900 using a Gatan CCD camera and DigitalMicrograph 3.0
software and saved as TIFF files. This resulted in 50 images per condition
(e.g., control vs. PMA treated). The SDs of caveolae, TEC, and the fenestrae
were counted on all the cells found in an image. The surface density was
estimated from the measured length of endothelium and considering the
thickness of a section of 50 nm.
RESULTS
PMA Upregulates PV1 mRNA and Protein Levels in ECs
in Culture
A strong correlation between the presence of PV1 and the
presence of SDs and FDs has been determined in situ where
PV1 was basically found only where the diaphragms are
found (Stan et al., 1999a, 1999b). Thus, PV1 antibodies stain
only the introits of caveolae provided with SDs and not the
caveolae lacking SDs. Similarly, fenestrae are stained by PV1
antibodies only if they are subtended by a FD and not in the
glomerulus where fenestrae have no diaphragms.
To see if the same correlation is valid in cell culture, we
checked whether conditions that induce the formation of the
diaphragms de novo would upregulate PV1. For this, we
used as a test an established cell culture model published by
Lombardi et al. (1986). In this model, the treatment of ECs in
culture with phorbol myristate acetate (PMA) induces the
formation of fenestrae and TEC. PMA is a diacyl glycerol
(DAG) analog and activator of several classes of molecules
such as PKC PKD, Ras-GRP, chimaerin, and Munc (Kazani-
etz, 2002). What is remarkable about this system is that the
fenestrae and TEC could be induced at varying surface
densities in human and bovine ECs isolated from different
vascular beds. Most importantly, these structures can be
induced even in those ECs (e.g., HUVEC) that lack the
diaphragms in situ or in cell culture, as previously shown
(Lombardi et al., 1987). Whether PMA treatment leads to the
formation of caveolar SDs in any of these cells was not
evaluated.
First, we looked at the effects of PMA treatment on PV1
expression levels in ECs in culture as well as in non-EC
types (HDF, HeLa, COS7, HEK293), for comparison. The
human ECs used were either from the microvasculature of
the lung (HLMVEC) or skin (HDMVEC-Ad, HDMVEC-neo)
or a large vessel such as the umbilical vein (HUVEC). We
chose these cell types as none of them contain any TEC or
fenestrae and their associated diaphragms in situ (Clementi
and Palade, 1969a; Simionescu et al., 1974; Milici et al.,
1985b). Only the lung microvascular ECs contain SDs at the
mouth of their caveolae in situ (Stan et al., 1999a, 1999b).
By RT-PCR, we found that PV1 mRNA levels were up-
regulated in time-dependent manner (Figure 1A) in the ECs
treated with PMA. This suggests that the PMA treatment
leads to transcriptional activation of the PLVAP gene. Ex-
tremely low levels of PV1 mRNA could be detected only in
control microvascular ECs (i.e., HDMVEC, HLMVEC; Fig-
ure 1A) but none in control large vessel ECs (i.e., HUVEC;
unpublished data). No PV1 mRNA was detected in either
control or PMA-treated non-EC types (HDF, HeLa, COS7,
HEK293) at any time (unpublished data).
PMA also upregulated PV1 protein, which became detect-
able at 12 h (Figure 1B, bottom panel) with ever-increasing
levels (Figure 1B, top panel) up 5 days, the longest time
point assessed. PV1 was undetectable in our assay in the
control human ECs (Figure 1B) and non-EC types (Figure
1F). Surprisingly, ECs from lung (HLMVEC), which had
been demonstrated to contain PV1 in situ (Stan et al., 1999a),
showed undetectable PV1 protein levels when kept in cul-
ture for 4–5 passages (Figure 1B, control lane). This adds to
the evidence showing dedifferentiation of ECs in culture.
The discrepancy between the RT-PCR data and immunoblot-
ting regarding the control could be explained by the much
lower sensitivity of the latter assay.
PMA upregulated PV1 in a dose-dependent manner; the
lowest effective PMA concentration was 0.5 nM (Figure 1C),
and PV1 upregulation was maximal at 50 nM. Higher
PMA doses (i.e., 500 nM) did not increase PV1 levels, sug-
gesting that the process is saturatable (unpublished data).
Treatment of ECs with dose of 50–500 nM phorbol dide-
canoate (PDD), an inactive PMA analog used as a negative
control to demonstrate specificity, failed to upregulate PV1
(see Figure 9A). This, in combination with the low PMA ED
(low nanomolar range  0.5 nM) and the dose and time
dependence, shows that the upregulation of PV1 is PMA
specific.
Treatment of non-EC cell types (HDF, HEK293, HeLa,
COS7; Figure 1D) with PMA in doses up to 500 nM did not
induce PV1 expression (Table 2). This lack of response was
not due to inactivation of the reagent upon handling, be-
cause PMA treatment of these cells resulted in PKC activa-
tion, as shown by immunoblotting with antiphosphoserine
PKC pseudosubstrate antibody (unpublished results). These
results correlate with the lack of phenotype changes seen by
light microscopy in these cells.
The Level of PV1 Upregulation by PMA Is Higher in
Microvascular than in Large Vessel ECs
Although PV1 was upregulated in all EC types, there were
remarkable differences with respect to the intensity of re-
sponse. Although the upregulation of PV1 was lowest in
HUVEC, the levels it reached in the microvascular ECs
(HDMVEC  HLMVEC) were 10–100-fold higher and this
was the true when the cells were plated at either low or high
density (Figure 2A and Table 2).
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This difference in PV1 upregulation was paralleled by
differences in cell shape change induced by PMA. A mor-
phological change from cobblestone to spindle-like shape
was observed within hours (between 8 and 24 h) in all
human ECs treated at high density/confluent monolayer
(Figure 2, C and F), confirming the previous findings (Lom-
bardi et al., 1987). This change in shape was accompanied
by marked attenuation of the periphery of the ECs due to
lamelipodia formation, as previously determined by EM.
Interestingly, although the shape of the PMA-treated
HLMVEC (unpublished data) or HUVEC (Figure 2E) plated
at 60% density was still spindle-like, the HDMVEC adopted
a flattened, “pancake-like” shape (Figure 2D). No apparent
shape change was detected in the control ECs where no
PMA was added (Figure 2, B and E).
These data show that the PV1 upregulation occurs in all
human ECs studied and bolster the marked phenotype dif-
ferences between endothelial cells according to vascular bed.
However, reasons for these differences are not clear and are
currently under investigation.
Most of the PV1 Induced by PMA Is Found on the Cell
Surface
To determine how much of the PMA induced PV1 is found
at the cell surface and how much inside the cell, we per-
formed surface biotinylation of plasma membrane proteins
of ECs (HUVEC and HDMVEC) as described in MATERI-
ALS AND METHODS. Biotin is a small molecule that pen-
etrates the intercellular junctions of the EC monolayers (very
leaky to begin with, in our cell culture conditions), thus
having access to both apical and basolateral aspects of the
plasma membrane. Total cellular extracts were clarified and
subjected to sequential incubations with neutravidin-aga-
rose (to bind the biotinylated cell surface proteins) and
anti-hPV1C pAb-agarose to bind the remaining (intracellu-
lar) pool of PV1.
As seen in Figure 3A, most of PV1 is found at the cell
surface after 2 and 5 days of continuous PMA treatment,
shown by immunoblotting with anti-PV1 antibodies. The
higher molecular weight band is chicken IgY that leaked
from the beads during boiling in SDS-PAGE sample buffer.
PMA Induces De Novo Formation of SDs and FDs That
Can Be Labeled with PV1 Antibodies
Previous work demonstrated the lack of diaphragms in
HUVECs in culture (Lombardi et al., 1987). Likewise, anal-
ysis by transmission electron microscopy (TEM) of the hu-
man ECs from control experiments (i.e., same time-length
Figure 1. PMA upregulates PV1 mRNA and protein only in ECs and not
in other cell types. (A) RT-PCR amplification using hPV1 specific primers
from 2 g mRNA purified from HDMVEC treated with PMA (D1–D5) or
control EC (C). The levels of the expected 200-bp band show time-depen-
dent upregulation of PV1 mRNA. “” negative and “” positive controls
for RT-PCR reaction. RT-PCR using GAPDH primers (GAPDH) served as
control for the relative amounts of mRNA used. (B) Time dependence of
the PV1 upregulation by PMA in HUVECs. Immunoblotting using the
anti-hPV1C antibody (PV1, two top panels) on PMA-treated or control
ECs. The two top panels represent different exposure times of the same
PV1 blot. The earliest time point PV1 protein was detected at was between
6 and 12 h (bottom panel). Immunoblotting with anti–-actin mAb on the
same membrane shows loading (Actin). Caveolin-1 levels remained the
same during PMA treatment (Cav1). (C) PV1 upregulation by PMA in
HUVECs is dose dependent. Note the low doses of PMA required for PV1
upregulation. (D) PV1 upregulation does not occur in nonendothelial cell
types exemplified by HDF. No PV1 was detected in these cells whereas
-actin (Actin, middle panel) and caveolin 1 (Cav1, bottom panel) are
readily detectable on the same membrane.







HUVEC Yes 1 Human
HLMVEC Yes 14 Human
HDMVEC, adult Yes 69 Human
HDMVEC, neonate Yes 93 Human
Nonendothelial
HDF ND ND Human
HEK293 ND ND Human
HeLa ND ND Human
COS7 ND ND Primate
a Relative arbitrary units. The level of PV1 upregulation obtained in
HUVEC and measured by densitometry was considered as the unit.
Because the densitometry of the ECL signal is semiquantitative, the
mean relative values shown were rounded up to show the range.
ND, nondetectable.
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culture in absence of PMA) documented the absence of
caveolar SDs (Figure 4H) and the absence of TEC and
fenestrae (unpublished data). Noteworthy, is the loss of the
caveolar SDs in HLMVEC, in line with the loss of PV1
expression, as shown above.
The caveolae in each of the EC type studied had SDs as
early as 24 h after PMA treatment (Figure 4, B and C, and
Table 3) in addition to fenestrae (Figure 4, A, B, G, and I) and
TEC (Figure 4, B and I), as shown by TEM micrographs.
Quantitative analysis of the surface density of SDs, TEC and
fenestrae induced by PMA in different cell types is presented
in Table 3. Note that the surface density of fenestrae in
HUVEC falls in the same order of magnitude with the
previously reported data (Lombardi et al., 1987). We have
expanded the survey to several other ECs as well as nonen-
dothelial cell types. Surprisingly, the kinetics and magnitude
of the formation of SDs and FDs were drastically different
according to the EC type. Although in HUVEC fenestrae and
TEC appeared only after 2 or more days of culture in pres-
ence of PMA, in the microvascular cells (most notably HD-
MVEC) they were present as soon as 16–24 h at much higher
surface density (i.e., two orders of magnitude difference)
than in their large vessel counterparts. The number of
fenestrae and TEC found decreased from HDMVEC-neo 
HDMVEC-Ad  HLMVEC  HUVEC, which parallel the
PV1 levels (Tables 3 and 2, respectively). Preliminary data
also showed that the surface density of the SDs and FDs in
HDMVEC is dependent on the commercial source of the
cells (unpublished results), which presumably indicates dif-
ferences in the isolation of the ECs. No SDs or FDs were
Figure 2. The phenotype changes induced by PMA
depend on the type of EC. (A) The levels of PV1 are
highest in HDMVEC  HLMVEC  HUVEC at 24 h
post-PMA treatment. The difference was as high as
two orders of magnitude as detected by densitometry
of the signal obtained by immunoblotting in cell
treated at both low (60%) and high (100%) density.
(B–G) PMA induces characteristic morphological
changes in human ECs. The change in phenotype dif-
fers according to the EC type (e.g., macro vs. micro-
vascular) and their density/proliferative state. HDM-
VEC (B–D) and HUVEC (E–G) either confluent (C and
F) or at 60% confluence (D and G) were serum-starved
followed by treatment with 30 nM PMA in SSM (see
MATERIALS AND METHODS) for 24 h before phase
contrast images were taken. Control cells (B and E).
(B–G) Bar, 3 m.
Figure 3. Most of PV1 protein is found on the cell surface. Immuno-
blotting with anti-hPV1C pAb of proteins bound to either neutravidin
(NA) or anti-PV1 (PV1) from extracts obtained from either control ECs
or ECs treated with 50 nM PMA for 2 or 5 days, showing that most of
PV1 in on the cell surface.
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detected in control (Figure 4E) or PMA-treated human der-
mal fibroblasts (Figure 4F), HeLa, HEK293 or COS7 (unpub-
lished results).
To see whether these newly formed SDs and FDs con-
tain PV1 or not, we localized the protein in ECs treated
with PMA by immunogold labeling using anti-hPV1C
pAb. PV1 was specifically associated with the newly
formed SDs and FDs (Figure 4, G and I). This demon-
strates that the same correlation between the presence of
the diaphragms and the presence of PV1, shown previ-
ously in situ (Stan et al., 1999a, 1999b), is maintained in
cells in culture. In favorable sections, several gold parti-
cles were found per diaphragm (Figure 4, G and I). No
label was found on either plasmalemma proper, coated
pits, or intercellular junctions. Similar results were ob-
tained in all ECs studied.
The quantitative analysis of the presence of the TEC and
fenestrae was fairly easy to perform (Table 3). However, the
presence of the SDs of caveolae was much harder to dem-
onstrate. The reason is that their diameter is smaller (25–40
Figure 4. PMA induces de novo formation of fenestrae, TEC, and caveolar SDs only in ECs (A and D, and G and I) but not in non-EC types
such as fibroblasts (F) as demonstrated by routine morphology of LX-112–embedded specimens. PMA induces fenestrae with FDs (A and B,
and G and I), TEC with SDs (B and I) and caveolar SDs (C–D and I) in HUVEC. The newly formed FDs and SDs contain PV1 as demonstrated
by immunogold labeling with anti-hPV1C pAb followed by a 6-nm gold-conjugated reporter antibody (G and I). Caveolae from control
HUVECs do not have SDs and do not stain with PV1 antibodies (H). Similar results were obtained in HDMVEC or HLMVEC. Caveolae from
either control (E) or PMA-treated (F) HDF do not stain with anti-PV1 antibodies and do not have SDs. Arrows point to either SDs or FDs.
Arrowheads point to the insertion point of the SDs in the neck of caveolae. Bars, 100 nm.
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nm) than the thickness of a standard section (50–70 nm). In
any given section, the number of caveolae that were cut
under an incidence that would allow the unequivocal dis-
crimination of the presence of the SDs was small (Table 3).
Basically, in order to see the SD in the neck of caveola, the
latter has to be still attached to the plasma membrane and
the SD has to be cut in such a way as to leave any portion or
the rim of the caveolar neck out of the picture. For this the
standard (50–70 nm) sections were clearly inappropriate.
The detection of the SDs was improved by reducing the
section thickness to 30–40 nm, which enabled unambiguous
morphological identification of the SDs in a fraction of the
total number of caveolar profiles on a given section (Table 3).
Specimen tilting at various angles in the microscope allowed
us to detect caveolar SDs in even higher numbers. This
enabled the unbiased collection of statistically significant
data in conditions of adequate sampling (Table 3). Most
importantly, in the PMA-treated samples most (98%)
caveolar necks that allowed a clear assessment of the pres-
ence of the diaphragm had a SD. The level of confidence of
the SD presence was further increased by the use of anti-PV1
immunocytochemistry, although this was chiefly used to
demonstrate the correlation between presence of the dia-
phragms and PV1 expression.
Admittedly, even these combinations of techniques did
not allow assessing whether all caveolae had SDs labeled by
anti-PV1 antibodies. There were few instances where we
have encountered caveolae-like vesicular profiles that were
labeled by the antibody and where it was impossible to
determine whether there was a diaphragm and conversely,
vesicular profiles that contained a diaphragm but were not
labeled by the antibody (Table 3). Although the former
discrepancy is clearly a technical limitation in detection, the
latter most probably means incomplete antibody labeling,
which is a common occurrence.
The imperfections in detection of the SDs do not hurt the
overall conclusions. The lack of diaphragms was previously
demonstrated by other investigators by both TEM and
freeze-fracture in the case of HUVECs (Lombardi et al.,
1987). This is in agreement with our data that correlate the
lack of SDs or FDs and lack of PV1 in the control ECs.
Furthermore, PV1 presence clearly correlates with the phys-
ical presence of the SDs of TEC and FDs of fenestrae induced
by PMA. Although we were not able to assess the presence
of the SDs in all caveolae, we were able to show it for
significant numbers.
Thus, in keeping with the data obtained in situ (Stan et al.,
1999a, 1999b), the strong correlation between the presence of
the diaphragms and presence of PV1 is maintained in cells in
culture, which is important to bear in mind.
The above results show that conditions that induce the
formation of the SDs and FDs lead to the upregulation of
PV1, which can be found within the de novo formed struc-
tures, in several copies per diaphragm. This further vali-
dates the close temporal and spatial correlation between PV1
and the FDs of fenestrae in situ and those induced in culture
are the same, in addition to the published EM data (e.g., by
rapid-freeze deep-etch) documenting their morphological
similarity (Lombardi et al., 1986).
Downregulation of PV1 mRNA with siRNA Prevents the
Formation of SDs and FDs
The next question was to see whether the silencing of PV1
mRNA and knockdown of the protein using small interfer-
ing PV1 RNA (PV1 siRNA) would prevent the formation of
the SDs and FDs induced by PMA. If successful, this exper-
iment would be the equivalent of the genetic deletion of the
PV1 gene. To achieve the silencing of PV1 mRNA we used
several PV1-siRNA duplexes, which we transfected into en-
dothelial cells 16–24 h before PMA treatment. The controls
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HUVEC 0.0079 0.0006 5% 17% 68.9% 81.16% – –
HLMVEC 0.99 0.0005 15% 21% 58.52% 63.7% – –
HDMVECneo 8.04 0.59 3% 13% 74.6% 75.2% – –
HDMVECAd 6.17 1.42 1% 24% 54.95% 70% 48% 56.61%
Controls NDc ND ND ND ND ND ND ND
SiRNA
HUVEC-PV1siRNA ND ND 1% 14% 3% 7% ND ND
HUVEC-scrsiRNA 0.0063 0.0006 6% 9% 72.9% 86.16% 37% 60%
HUVEC-nosiRNA 0.0095 0.0007 2% 21% 79.3% 82.13% 20% 31%
Transfections
HUVEC ND ND 7% 18% 68% 83% ND ND
HUVEC mock ND ND ND ND ND ND ND ND
HDF ND ND 1% 14% 53% 62% ND ND
HDF mock ND ND ND ND ND ND ND ND
–, represents experiments not done.
a The area was calculated considering the thickness of the sections as 50 nm.
b A fraction of the SDs identified by TEM or upon tilting was also labeled by anti-PV1 or anti-tag antibodies.
c ND, none detected.
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consisted of their scrambled siRNA counterparts. We pri-
marily used HUVEC for these experiments for two reasons:
i) HUVEC are devoid of PV1 expression and do not have
either SDs and FDs as determined by others and confirmed
by us (Table 2); ii) HUVEC were the most amenable cells to
transfection in combination with Targefect-siRNA reagent,
as determined by using a FITC-labeled siRNA (our unpub-
lished data).
First, we determined that two siRNA duplexes were par-
ticularly effective in downregulating the PV1 mRNA and,
most importantly, the PV1 protein. These siRNAs were
dubbed 258PV1-siRNA and 249PV1-siRNA (see MATERI-
ALS AND METHODS for sequence information). The
258PV1-siRNA downregulated up to 98% of the PV1 protein
(Figure 5A) at doses as low as 75 pmoles/well, whereas
249PV1-siRNA was this effective at higher dose (200
pmoles/well). This result was also confirmed by immuno-
fluorescence with anti-hPV1C pAb (Figure 5B, bottom pan-
els). The PV1 levels in HUVEC treated with scrambled PV1-
siRNA were roughly the same as those induced in a
nontreated control cell (Figure 5A, right panel).
We then compared by EM analysis PMA-treated HUVECs
that have been previously transfected with either the PV1-
siRNA, scrPV1-siRNA control, or no siRNA treatment con-
trol. The goal was to demonstrate the lack of the SDs and
FDs in the PV1-siRNA–treated cells upon PMA treatment,
compared with the controls. As above, to help with the
quantitative aspect of EM we have performed specimen
tilting and labeling with gold-conjugated anti-hPV1C anti-
bodies. As expected, we did not detect any labeling with
anti-hPV1C antibody in the PV1-siRNA–treated samples, in
marked contradistinction with the scrPV1-siRNA control or
untreated control, where roughly 70% of the caveolae were
labeled. The SDs and FDs (Table 3) in the PMA-treated
controls (Figure 5C, top panel) were readily present and
labeled by the anti-PV1 antibody, in high contrast with the
marked absence of both the SDs and gold label on the
PV1-siRNA–treated ones (Figure 5C, bottom panel). Most
Figure 5. PV1 down-regulation
by siRNA prevents the formation
of the diaphragms in PMA-
treated HUVEC. (A) Immunoblot-
ting with anti-hPV1C pAb. The
treatment of HUVEC with two in-
dependent PV1-siRNAs prevents
the upregulation of PV1 by PMA
(left panel), whereas the scram-
bled siRNA does not (right
panel). (B) Colocalization of PV1
and caveolin-1 by immunofluo-
rescence with anti-hPV1C pAb
(red) and anti-Cav1 pAb (green).
In HUVEC treated with 75 pmol
of 258PV1-siRNA, PV1 is effec-
tively downregulated, whereas
scrambled siRNA (scr) has no ef-
fect. Bar, 2 m. (C) The down-
regulation of PV1 by 258PV1-
siRNA prevents the formation of
caveolar SDs as shown by EM
(bottom panels). Both SDs and
FDs are present and can be la-
beled with anti-PV1 pAb in con-
trol cells treated with scrambled
siRNA (scr, top panels).
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importantly, in the siRNA-treated samples none of the
caveolar necks that allowed a clear assessment of the pres-
ence of the diaphragm had an SD present. The quantitation
data have been incorporated in Table 3 and clearly show that
PV1 downregulation by siRNA prevents the formation of
the SDs. A notable finding was that no fenestrae or TEC
were detected in the PV1siRNA–treated samples, which im-
plies that PV1 is required for their formation.
The data from these crucial experiments strongly suggest
that PV1 is necessary for the formation of SDs and FDs.
Overexpression of Exogenous, Tagged PV1 Shows
Colocalization With Caveolin 1 at the Level of Plasma
Membrane of Cells in Culture
Another way of looking at the role of PV1 in the formation
of the diaphragms is the reverse experiment, that is, to see
whether over expression of PV1 in both ECs and nonendo-
thelial cell types (e.g., HDF, HeLa, COS7, HEK293) lacking
both SDs and FDs would result into a diaphragm pheno-
type. We first characterized the PV1 overexpression con-
structs in order to make sure that they express a correct
protein that is trafficked to the correct location in the cell (i.e.,
caveolae).
To aid the detection of the exogenously introduced pro-
tein, human PV1 was tagged with either FLAG (hPV1-
FLAG) or HA (hPV1-HA) epitopes at its C terminus, which
is extracellular. In most experiments, the epigenetic expres-
sion of tagged hPV1 was from bicistronic vectors that also
encoded for a humanized green fluorescent protein from
Renilla (hrGFP). hrGFP expression was used for the identi-
fication of transfected cells in imaging experiments as well
as to judge the transfection efficiency for biochemistry and
EM experiments.
Immunoblotting of proteins from ECs or non-EC types
after transfection with either of the constructs (i.e., hPV1-
FLAG or hPV1-HA) with the appropriate antitag antibody
as well as anti-hPV1C pAb, showed a single band at the
appropriate MW size (60 kDa; Figure 6A). The band im-
munoprecipitated by either anti-FLAG or anti-HA mAb was
recognized by blotting with anti-hPV1C pAb (Figure 6B); the
reverse experiment (immunoprecipitation with anti-PV1
and blot with corresponding antitag) was also positive (Fig-
ure 6C). These demonstrate that the correct protein sequence
was expressed.
To determine the size of the tagged PV1 pool that was able
to reach the plasma membrane, we have performed surface
biotinylation followed by sequential pull-down with neutra-
vidin and anti-PV1, as already described. As seen in Figure
6D, 75% (average of three independent experiments) of
PV1 can be biotinylated on the cell surface at 48 h posttrans-
fection, consistent with a large PV1 pool at the level of the
plasma membrane.
In keeping with this, we found a punctuated pattern at the
level of the plasma membrane in transfected nonpermeabi-
lized cells (Figure 7A) by immunofluorescence using antitag
antibodies (i.e., anti-FLAG mAb and anti-HA mAb). The
same pattern was found when hPV1 was tagged with either
FLAG or HA epitopes demonstrating that this localization is
tag-independent (unpublished data).
Finally, to determine whether the overexpressed hPV1
traffics correctly to the neck of caveolae, we have colocalized
it with caveolin 1, the most accepted caveolar marker (Kur-
zchalia et al., 1992; Rothberg et al., 1992; Dupree et al., 1993).
As seen in Figure 7B, PV1 significantly colocalizes with
caveolin 1-mRFP at the cell surface in cotransfection exper-
iments in live endothelial cells (see MATERIALS AND
METHODS and figure legend). Similarly, PV1-HA colocal-
ized with native caveolin 1 in permeabilized fixed ECs (un-
published data) and fibroblasts (Figure 7C) or other non-EC
types (e.g., HeLa, COS7, and HEK293; unpublished data).
Expression of Tagged PV1 Induces Formation of only SDs
That Can Be Stained with Antitag Antibodies
We next looked using EM if overexpression of hPV1 would
lead to formation of the diaphragms or not. For this we used
both ECs (HUVEC) and fibroblasts (HDF) that do not have
caveolar SDs and do not express hPV1 either in situ or in
culture. To be used for EM studies, the cell population
needed to have a high content of transfected cells. Because of
low transfection efficiency of these cell types by most avail-
able transfection reagents, we electroporated (“nucleo-
fected”) HUVEC (60–70% efficiency by flow cytometry)
and HDF (80–85% efficiency) using the Nucleofector de-
vice. The “nucleofection” has the advantage to be very effi-
cient for cell lines hard to transfect and delivers the DNA
directly to the nucleus, resulting in expression of the protein
as soon as 2–4 h posttransfection. Because of high efficiency,
it also did not require detachment of the cells after PV1 was
expressed. However, this is a relatively new technology,
which still awaits a full explanation of its mechanism. There-
fore, we also used an alternate transfection strategy for
control, where we transfected HUVEC using the Targefect
F1 (20 –30% efficiency) reagent followed by cell dissoci-
ation in a trypsin-free buffer and isolation of the trans-
Figure 6. Validation of huPV1-HA or huPV1-Flag constructs
and demonstration of their cell surface pool. (A) Western blotting
using anti-FlagM2 mAb of total cell lysates of HUVECs mock-trans-
fected with pIRES-hrGFP-1a empty vector (Mock) or transfected with
0.1 (0.1) or 0.4 (0.4) g of huPV1-Flag plasmid DNA. (B) Immunopre-
cipitations using either anti-HA or anti-Flag of either huPV1-HA or
huPV1-Flag proteins, respectively, immunoblotted with anti-huPV1C
pAb. (C) Immunoprecipitations of either huPV1-HA or huPV1-Flag
proteins from HUVEC lysates, using anti-huPV1C pAb, immuno-
blotted with either anti-HA or anti-Flag, respectively. (D) Immunoblot-
ting with anti-PV1 of proteins bound to either neutravidin (NA) or
anti-PV1-agarose (PV1) resulted from surface biotinylation of control
cells or cells transfected with either empty vector (mock) or with
PV1–3xHA (PV1-HA). Data in D are representative for at least three
independent experiments.
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fected cells by FACS. To eliminate dead cells and avoid possi-
ble artifacts due to loss of adhesion, the isolated cells were
replated at high density (85%) and allowed to reattach for
20 h before fixation. We did not find any reagent that yielded
satisfactory results for HDF transfection (1% with the most
efficient reagent); therefore, we used other cell types such as
HeLa, Cos7, or HEK293 for this type of experiment. The DNA
transfected was either hPV1-HA or hPV1-Flag encoded in a
bicistronic vector also expressing hrGFP. In both sets of exper-
iments (nucleofection vs. transfection) cells were fixed and
processed for immunogold labeling with antitag antibodies to
follow the exogenous protein and then resin embedded. Sim-
Figure 7. Transiently expressed PV1–3xHA
colocalizes with caveolin 1 at the cell surface
in either ECs (A and B) or fibroblasts (C). (A)
Immunofluorescence with anti-HA mAbs
(red) demonstrating the staining in fixed,
nonpermeabilized ECs transfected with
hPV1–3xHA_IRES_hrGFP construct. HrGFP
(green) demonstrates the transfected cells.
Bars, 10 m. (B) Colocalization by immuno-
fluorescence of PV1-HA (green) and caveolin
1-mRFP (red) in live ECs. An overlay of a
brightfield image (bottom left panel) and the
hrGFP staining (blue) demonstrates a cell
transfected with the hPV1–3xHA_IRE-
S_hrGFP construct. The bottom right panel
(Merge) shows the signal obtained from
hrGFP (blue), caveolin 1-mRFP (red), and
PV1-HA (green). The staining obtained with
anti-HA mAb is shown in green in the top
right panel (PV1-HA) and the pattern ob-
tained with caveolin 1-mRFP in the top left
panel (Caveolin 1-mRFP). The white squares
indicate the area shown enlarged (3) in the
insets. Bars, 10 m (C). Colocalization of PV1–
3xHA and native Caveolin 1 in permeabilized
human dermal fibroblasts as demonstrated by
epifluorescence. Due to high signal obtained
from ER and Golgi in the case of PV1–3xHA
overexpression, only peripheral parts of the
cells were imaged in permeabilized cells.
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ilar results have been found with both transfection strategies
(see below).
As seen in Figure 8, the caveolae in both ECs (Figure 8,
B–E) and non-EC types (i.e., HDF; Figure 8, G and H)
transfected with tagged hPV1 were provided with SDs
that were labeled with antitag antibodies. This demon-
strated that the exogenous hPV1 protein participates in
the formation of these diaphragms. No gold particles
were found on either plasmalemma proper, coated pits, or
intercellular junctions. Also, no gold particles were found
on the controls where the primary antibody was either
replaced with an irrelevant, isotype matched mouse IgG
or omitted altogether. Moreover, no TEC or fenestrae
were detected in these cells after extensive surveys of the
samples, suggesting that PV1 expression is not enough for
the expression of these structures. This lack of fenestrae
and TEC is not unexpected, because this very phenotype
is usually found in situ in the continuous endothelium of
the lung, tongue, or kidney vasa recta.
The quantitative aspects of the overexpression experi-
ments are shown in Table 3. Again the unambiguous dem-
onstration of both the label and SDs occurred on a relatively
small number of caveolae in transfected cells. However, the
contrast between this and the complete lack of label and SDs
in the controls are indicative of the fact that PV1 is a key
component for SD formation. What bolsters this conclusion
is the fact that PV1 forms SDs in cells that do not have them
in situ, such as HDF.
Signaling Pathways Involved in the Upregulation of PV1
by PMA
The Upregulation of PV1 by PMA is PKC Independent PMA
is a known activator of PKC but recent findings have shown
that it can also activate at least four other classes of proteins
including Ras-GRP (an activator of Ras GTPase), chimaerin
(an GAP/activator of Rac1 GTPase), PKD, and Munc13 (re-
viewed in Kazanietz, 2002).
To ascertain whether PV1 upregulation by PMA is PKC
dependent, we looked at the PV1 levels in ECs treated with
PMA in presence of pharmacological inhibitors of PKC. We
found that inhibition of the kinase enzymatic activity of PKC
by bisindolylmaleimide and Go6983 at concentrations of
10–500 nM did not inhibit PV1 upregulation by PMA (Fig-
ure 9A and unpublished data). Moreover, staurosporine,
also an inhibitor of PKC catalytic activity, had a synergistic
effect with PMA, increasing the PV1 levels in dose-depen-
dent manner (Figure 9B). Although the doses used (0.5–50
nM) were well within the interval of “specificity” for PKC
inhibition, staurosporine is a rather promiscuous inhibitor
that inactivates several other classes of kinases including
PKA and Akt and can interfere with other pathways. This
suggests that another kinase could be involved in PV1 reg-
ulation.
Because all these inhibitors have issues of stability in solu-
tion, we performed controls to demonstrate their activity. Im-
munoblotting with antiphosphoserine PKC pseudosubstrate
antibody (PS-PKC-PS) showed marked increase in staining in
Figure 8. Overexpression of PV1 in cells
that lack PV1 and both FDs and SDs results
in formation of caveolar SDs. Electron mi-
crographs of cells transfected (by nucleofec-
tion) with huPV1-Flag construct showing
that caveolae are provided with SDs in
HUVECs (B–E) or HDF (G–H) while the SDs
lack in empty vector transfected control
HUVEC (A) or HDF (F). The newly formed
diaphragms can be labeled with anti-FLAG
mAb (B, C, G, and H) showing that the
exogenous PV1 protein participates in their
structure. In favorable sections, several gold
particles were detected in one diaphragm (G
and H). Arrows point to labeled dia-
phragms. Bars, 50 nm.
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the control PMA-treated cells compared with untreated ECs,
whereas the staining markedly decreased in the samples
treated with PMA plus inhibitors (unpublished data).
The Upregulation of PV1 by PMA Is Dependent on the
Activation of a C1 Domain–containing Protein We also
found that calphostin C, an inhibitor that competes the
binding of DAG/PMA to the C1 domain of PKC and other
C1 domain–containing proteins, inhibits PV1 upregulation
at doses of 10–100 nM (Figure 9A and our unpublished
data).
Taken together, these data show that PV1 upregulation by
PMA is PKC independent. The data obtained with stauro-
sporine treatment indicates that yet another kinase might be
involved in PV1 regulation. The inhibition observed after
calphostin C treatment demonstrates that a C1 domain–
containing protein is required for the upregulation of PV1.
PV1 Upregulation Requires the Activation of Erk1/2 MAP
Kinase Pathway Another well-known effect of PMA is the
activation of Erk1/2 MAP kinase pathway (Frost et al., 1994;
Verin et al., 2000). At least three of the five protein classes
directly activated by PMA (i.e., PKC, Ras-GRP, chimaerin)
could transduce their transcriptional signals via the MAP
kinase pathway (Kazanietz, 2002). To see whether this path-
way could affect PV1 regulation, we treated the cells with
MAP kinase inhibitors.
As shown in Figure 10A, treatment of human ECs with
PMA led to the activation of the components of the Erk1/2
pathway, which led to the activation of Elk1 transcription
factor. Elk1 is a known carrier of the transcriptional effects of
Erk1/2 (Cobb, 1999)and therefore a putative regulator of
PLVAP gene. However, whether this is true or not needs
more thorough investigation.
Treatment of ECs with inhibitors of MEK1 (kinase imme-
diately upstream of Erk1/2), such as PD98059 (0.25–25 M)
and U0126 (1–10 M), prevented the upregulation of PV1 by
PMA in dose-dependent manner, whereas the inactive com-
pound U0124 did not have any effect (Figure 10B). More-
over, the inhibition of MEK1 abolished also the lamelipodia
formation induced by PMA in these ECs (Figure 10A).
DISCUSSION
The work presented here is a result of our interest on the
elucidation of the molecular components of the structures
involved in transendothelial exchanges. Using our purifica-
tion method of endothelial caveolae (Stan et al., 1997) and
taken advantage of a novel antiendothelium antibody (Ghi-
tescu et al., 1997), we have identified and cloned PV1, an
endothelial specific protein (Stan et al., 1999b). We have
further shown PV1 to be specifically associated with the SDs
of caveolae and TEC as well as with the diaphragms of
fenestrae in situ. Moreover, several PV1 dimers were shown
to reside in one diaphragm (either SDs or FDs) by immuno-
cytochemistry (Stan et al., 1999a, 1999b) and by cross-linking
(Stan, 2003). This was the first demonstration that these
structures, besides being morphologically similar, were also
biochemically related sharing at least one protein, namely PV1.
The function of the diaphragms is not known. By their
localization at proposed sites of transendothelial exchange,
one could assume that they function either as a sieving
device (opposing the exchanges of select molecules) or a
facilitating device (enabling selective transport of molecules)
or both.
As for the presence of PV1 on such diaphragms, it could
function as either a structural component, function modula-
tor component or both. To gain insight into the function of
PV1 in the diaphragms, we have carried out experiments by
several approaches that address this issue.
First, we turned to a cell culture system where transendo-
thelial channels and fenestrae could be induced de novo in
any EC type by phorbol esters such as PMA (Lombardi et al.,
1985, 1986, 1987, 1988). For this, we used several human EC
types isolated from vessels provided with continuous endo-
thelia, such as large vessels (umbilical vein) as well as from
the microvasculature (skin and lung). These comprised ECs
whose caveolae do not have SDs (e.g., HUVEC, HDMVEC;
Stan et al., 1999b) and ECs whose caveolae are provided with
SDs (e.g., lung), in situ. HUVEC were particularly useful as
their caveolae were shown to lack SDs by other groups and
also provided a control for our ability to reproduce previ-
ously reported findings. For controls, nonendothelial cell
types that lack both the structures and the protein were
used.
On treating the cells with PMA only the human EC types
underwent the characteristic morphological changes as pre-
viously reported by Lombardi et al. (1985, 1986, 1987, 1988).
The changes in cell shape differed according to the EC type
(e.g., microvs. macrovascular) and to the proliferative or
quiescent state of the cell and ranged from fibroblast-like
(e.g., HUVEC, HLMVEC and confluent HDMVEC) to ex-
tremely flat “pancake-like” shape (e.g., subconfluent HDM-
VEC). No detectable change in shape occurred in non-EC
types by simple inspection of the culture.
At biochemical level, we show that ECs in culture lack
PV1 expression. Moreover, even cells that do express PV1 in
situ lose it by the fourth passage (the earliest passage we
looked at), such as in the case of HLMVEC. We found that
PMA treatment upregulates hPV1 mRNA and protein in
time- and dose-dependent dependent manner. Again there
Figure 9. PMA-induced PV1 upregulation is PMA specific and
does not require the kinase activity of PKC in ECs. (A) Western
blotting using the anti-hPV1C antibody (PV1, two top panels) and
anti -actin mAb (Actin, bottom panel) on proteins from either
control ECs or ECs treated with 30 nM phorbol didecanoate, an
inactive PMA analog, 30 nM PMA, 500 nM bisindolylmaleimide I,
500 nM Go6893, and 100 nM calphostin C. The lack of effect of PDD
and the inhibition of DAG competitor calphostin C show that PMA
specifically upregulates PV1. Both PKC kinase activity inhibitors
bisindolylmaleimide I and Go6983 were without effect, showing
that PV1 upregulation by PMA is PKC independent. (B) Staurospor-
ine, another inhibitor of PKC kinase activity, has a synergistic effect
with PMA, augmenting the PV1 levels in dose-dependent manner.
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were marked differences between the micro- and macrovas-
cular ECs in terms of levels of PV1 expression upon PMA
treatment. The highest level of induction occurred in HDM-
VEC, which paralleled the morphological changes. The PV1
upregulation did not occur in non-EC types. Thus conditions
known to induce the de novo formation of SDs and FDs also
induce the expression of PV1.
By EM, we show that all untreated human ECs examined
in culture lack diaphragms (both SDs and FDs). In the case
of the HLMVEC this correlates the biochemical data show-
ing loss of PV1 expression. Remarkably, PMA treatment of
human ECs leads to formation of the TEC and fenestrae,
with their associated diaphragms. We found that the caveo-
lar SDs were also induced in cells treated with PMA. Please
note that in the PMA-treated ECs the level of induction of
PV1 protein directly correlates with the level of induction of
SDs and FDs (i.e., both are highest in HDMVEC). Addition-
ally, most of the PV1 protein induced by PMA was found at
the cell surface as shown by biochemistry (e.g., surface bi-
otinylation) at time points that were evaluated by EM. As
expected, the de novo formed diaphragms could be labeled
with anti-hPV1C pAb.
Moreover, in crucial experiments in which the PV1 mRNA
was silenced and the PV1 protein downregulated 95%, we
show that the diaphragms do not form in the absence of
PV1. These data strongly suggest that PV1 is a key structural
element of the diaphragms.
Another important experiment to do was to see whether
the transfection of ECs in culture with tagged PV1 would
restore the diaphragms or not. Our findings show that in-
deed, transfection of ECs with tagged PV1 leads to forma-
tion of SDs that could be labeled with antitag antibodies.
Moreover, PV1 transfection in the non-EC cell types leads to
formation of SDs at the mouth of their caveolae. These data
bring further support the idea of PV1 being necessary for the
formation of the diaphragms.
Figure 10. Erk1/2 MAP kinase activity is
required for the upregulation of PV1 as well
as for the morphological changes induced by
PMA in ECs. PMA activates the Erk1/2 MAP
kinase pathway in ECs as demonstrated by
immunoblotting with phospho-specific anti-
bodies to components of the pathway such as
MEK1, Erk1/2, and Elk-1, a downstream ef-
fector of Erk1/2 (F). MEK1, Erk1/2, and -ac-
tin (to show the loading, Actin) were probed
on the same membrane. (G) Inhibitors of
MEK1 such as U0126 and PD98059 prevent
the upregulation of PV1 by PMA in a dose-
dependent manner, as shown by immunoblot-
ting with anti-PV1C pAb. U0124, an inactive
analog of U0126 is without effect. Immuno-
blotting with anti -actin mAb shows the
loading (Actin). Same inhibitors of MEK1,
U0126 (D), and PD98059 (E), prevent the phe-
notype change of ECs induced by PMA (A),
whereas U0124 has no effect (C). Control ECs
(A) treated with 50 nM PMA or (B) without
treatment.
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It is not unexpected that only caveolar SDs are detected
upon PV1 transfection. A possible explanation is suggested
by the existence in situ, in the intact animal, of endothelial
caveolae with (e.g., in lung, endocrine glands, kidney vasa
recta, tongue) and without (e.g., in myocardium, skeletal
muscle, skin) SDs, and fenestrae with (e.g., in all endocrine
glands, kidney peritubular capillaries, intestine vili) and
without FDs (e.g., in kidney glomerulus). A reasonable
enough interpretation of this situation is that the signals that
concur to the formation of SDs or FDs are different from
those involved in the biogenesis of caveolae or fenestrae,
respectively. In other words, the component(s) of the dia-
phragms would form the diaphragm if a preexisting struc-
ture (e.g., caveolar invagination or fenestral pore) would be
available. Thus, by expressing exogenous PV1 in ECs in
culture, one finds only SDs because only caveolae are
present in these cells in culture, this mimicking the pheno-
type found in ECs in the lung in situ. More remarkably, the
fact that the SDs were formed even in ECs and nonendothe-
lial cell types that do not have PV1 in situ, such as HUVEC,
HDMVEC, and HDF (as well as HeLa, COS7, and HEK293),
shows that either i) PV1 alone is sufficient to form the
diaphragms or ii) the other putative constituents of the
diaphragms (e.g., intracellular proteins) are ubiquitously ex-
pressed and PV1 is the key limiting component. Our pre-
liminary data obtained in other systems (e.g., yeast two
hybrid and affinity chromatography) point to the second
situation to be true. Therefore, it is far from us to sustain that
PV1 is the only component necessary for the formation of
these diaphragms. What our data have proven so far is that
PV1 is present into both SDs and FDs and that it is necessary
for diaphragm formation, our case being stronger in the case
of the SDs.
Finally, we probed into the signaling pathways that might
be involved in PV1 regulation. The PMA effect seems to be
PKC independent because none of the PKC kinase activity
inhibitors (i.e., BIM and Go6983) prevent/inhibit the up-
regulation of PV1. Even further, staurosporine, another PKC
kinase inhibitor, increased the levels of PV1. Only calphostin
C, a DAG/PMA competitor for binding to the C1 domain of
PKC and other PMA targets, inhibited the upregulation.
Because at least three other classes of C1 domain–containing
proteins unrelated to PKCs (e.g., chimaerin, Munc13, Ras-
GRP) have been already described (Kazanietz, 2002), this
result demonstrates the involvement of a C1 domain–con-
taining protein in the signaling cascade leading to PV1 up-
regulation. It would be of interest to see whether any of
these classes of proteins would have a role in the regulation
of PV1 as well as SD and FD formation. For example chi-
maerin, one of the proteins activated by PMA, activates Rac1
GTPase, which in turn has a well documented role in con-
trolling lamelipodia formation, thus providing an explana-
tion for the EC phenotype changes seen by light microscopy.
The use of PMA in this system also prompted us to look
at the involvement of MAP kinase Erk1/2 in the PV1 up-
regulation. Using pharmacological inhibition of MEK1, the
kinase upstream of Erk1/2, we found that its activation is
required by both cytoskeletal rearrangements as well as PV1
upregulation. This would be in line with the data showing
upregulation of the fenestrae and TEC by growth factors
such as VEGF (Roberts and Palade, 1995; Roberts et al., 1997;
Esser et al., 1998), which is also known to activate the MAP
kinase pathway via Ras. A more detailed analysis of the
pathways involved in PV1 upregulation is currently underway.
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